The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The Bcl-2 Protein Family: Arbiters of Cell Survival
Adams, J. M., & Cory, S. (1998) · Science · doi:10.1126/science.281.5381.1322 · Cited by 5,332
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“2 ; Table 1 ), was found to disrupt HDM2–p53 complexes with an IC 50 of 90 nM, and it showed potent p53-blocking activity in vitro and activity against tumour xenografts in vivo”
BackgroundDrug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Global landscape of protein complexes in the yeast Saccharomyces cerevisiae
Krogan, N. J., Cagney, G., Yu, H., Zhong, G., Guo, X., Ignatchenko, A., Li, J., Pu, S., Datta, N., Tikuisis, A. P., et al. (2006) · Nature · doi:10.1038/nature04670 · Cited by 2,952
Principles of protein-protein interactions
Jones, S., & Thornton, J. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.13 · Cited by 2,684
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Cited by
Items 101–146 of 146
DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
Li, F., Hu, Q., Zhang, X., Sun, R., Liu, Z., Wu, S., Tian, S., Ma, X., Dai, Z., Yang, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34807-3 · Cited by 159
“Despite the great success, this MOA suffers from several limitations such as inability to deal with undruggable targets 1 – 3 , off-target toxicity 4 , undesired side effects 5 , drug resistance 6,7 , and so on.”
Background2P2Idb: a structural database dedicated to orthosteric modulation of protein–protein interactions
Basse, M. J., Betzi, S., Bourgeas, R., Bouzidi, S., Chetrit, B., Hamon, V., Morelli, X., & Roche, P. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1002 · Cited by 148
Identification of Protein Interactions Involved in Cellular Signaling
Westermarck, J., Ivaska, J., & Corthals, G. L. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r113.027771 · Cited by 143
Buchwald, P. (2010) · IUBMB Life · doi:10.1002/iub.383 · Cited by 133
Atomic Analysis of Protein-Protein Interfaces with Known Inhibitors: The 2P2I Database
Bourgeas, R., Basse, M.-J., Morelli, X., & Roche, P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009598 · Cited by 126
“preclinical stage of investigation [8,17].”
BackgroundTargeted manipulation of the sortilin–progranulin axis rescues progranulin haploinsufficiency
Lee, W. C., Almeida, S., Prudencio, M., Caulfield, T. R., Zhang, Y.-J., Tay, W. M., Bauer, P. O., Chew, J., Sasaguri, H., Jansen-West, K. R., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt534 · Cited by 125
Protein–protein interactions as targets for small-molecule therapeutics in cancer
White, A. W., Westwell, A. D., & Brahemi, G. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000641 · Cited by 122
Ni, D., Lu, S., & Zhang, J. (2019) · Medicinal Research Reviews · doi:10.1002/med.21585 · Cited by 116
“The development of modulators to tune PPIs in the treatment of human diseases has been an attractive goal in both basic and clinical research in recent decades, and immense efforts have been invested in relevant studies.(9,10)”
BackgroundTargeting Protein–Protein Interactions and Fragment-Based Drug Discovery
Valkov, E., Sharpe, T., Marsh, M., Greive, S., & Hyvönen, M. (2011) · Topics in Current Chemistry · doi:10.1007/128_2011_265 · Cited by 107
Anders, C., Higuchi, Y., Koschinsky, K., Bartel, M., Schumacher, B., Thiel, P., Nitta, H., Preisig-Müller, R., Schlichthörl, G., Renigunta, V., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.03.015 · Cited by 106
Hot-spot analysis for drug discovery targeting protein-protein interactions
Rosell, M., & Fernández-Recio, J. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1430763 · Cited by 105
“Known PPI inhibitors do not have high similarity to traditional inhibitors of enzymes and receptors [30], showing physicochemical properties that may violate traditional rules such as the Lipinski’s Rule of Five [88].”
BackgroundInfluentialNew Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design
Ray, S., & Murkin, A. S. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00293 · Cited by 108
Labbé, C. M., Laconde, G., Kuenemann, M. A., Villoutreix, B. O., & Sperandio, O. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.003 · Cited by 104
Discovery of new GPCR ligands to illuminate new biology
Roth, B. L., Irwin, J. J., & Shoichet, B. K. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2490 · Cited by 94
He, S., Senter, T. J., Pollock, J., Han, C., Upadhyay, S. K., Purohit, T., Gogliotti, R. D., Lindsley, C. W., Cierpicki, T., Stauffer, S. R., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401868d · Cited by 99
Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer
He, S., Ma, J., Fang, Y., Liu, Y., Wu, S., Dong, G., Wang, W., & Sheng, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.022 · Cited by 91
Birts, C. N., Nijjar, S. K., Mardle, C. A., Hoakwie, F., Duriez, P. J., Blaydes, J. P., & Tavassoli, A. (2013) · Chemical Science · doi:10.1039/c3sc50481f · Cited by 85
Basse, M.-J., Betzi, S., Morelli, X., & Roche, P. (2016) · Database · doi:10.1093/database/baw007 · Cited by 83
Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors
Gonzalez-Lopez de Turiso, F., Sun, D., Rew, Y., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Correll, T. L., Huang, X., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400293z · Cited by 82
Shigdel, U. K., Lee, S.-J., Sowa, M. E., Bowman, B. R., Robison, K., Zhou, M., Pua, K. H., Stiles, D. T., Blodgett, J. A. V., Udwary, D. W., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006560117 · Cited by 80
Small molecule modulators of protein-protein interactions: selected case studies
Aeluri, M., Chamakuri, S., Dasari, B., Guduru, S. K. R., Jimmidi, R., Jogula, S., & Arya, P. (2014) · Chemical Reviews · doi:10.1021/cr4004049 · Cited by 79
Sijbesma, E., Visser, E., Plitzko, K., Thiel, P., Milroy, L.-G., Kaiser, M., Brunsveld, L., & Ottmann, C. (2020) · Nature Communications · doi:10.1038/s41467-020-17741-0 · Cited by 72
Modulating Protein–Protein Interactions with Small Molecules: The Importance of Binding Hotspots
Thangudu, R. R., Bryant, S. H., Panchenko, A. R., & Madej, T. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.026 · Cited by 71
Plucking the high hanging fruit: A systematic approach for targeting protein–protein interactions
Raj, M., Bullock, B. N., & Arora, P. S. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.023 · Cited by 66
Increasing the efficiency of ligands for FK506-binding protein 51 by conformational control
Wang, Y., Kirschner, A., Fabian, A.-K., Gopalakrishnan, R., Kress, C., Hoogeland, B., Koch, U., Kozany, C., Bracher, A., & Hausch, F. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400087k · Cited by 60
Discovery of a small-molecule inhibitor of specific serine residue BAD phosphorylation
Pandey, V., Wang, B., Mohan, C. D., Raquib, A. R., Rangappa, S., Srinivasa, V., Fuchs, J. E., Girish, K. S., Zhu, T., Bender, A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1804897115 · Cited by 59
Li, Y., Li, W., & Xu, Z. (2021) · Marine Drugs · doi:10.3390/md19060311 · Cited by 59
DNA‐Binding Small Molecules as Inhibitors of Transcription Factors
Leung, C., Chan, D. S., Ma, V. P., & Ma, D. (2013) · Medicinal Research Reviews · doi:10.1002/med.21266 · Cited by 58
Yang, C.-Y., & Wang, S. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100276b · Cited by 57
Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids
Wang, H., Teriete, P., Hu, A., Raveendra-Panickar, D., Pendelton, K., Lazo, J. S., Eiseman, J., Holien, T., Misund, K., Oliynyk, G., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6116 · Cited by 53
“Discovery of methyl 4’-methyl-5-(7nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1’-biphenyl]3-carboxylate, an improved small-molecule inhibitor of c-Myc-max dimerization.”
BackgroundInfluentialCierpicki, T., & Grembecka, J. (2015) · Immunological Reviews · doi:10.1111/imr.12244 · Cited by 53
Golden, M. S., Cote, S. M., Sayeg, M., Zerbe, B. S., Villar, E. A., Beglov, D., Sazinsky, S. L., Georgiadis, R. M., Vajda, S., Kozakov, D., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja400914z · Cited by 47
Niedermolekulare PROTACs: neue Wege zum Abbau von Proteinen
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie · doi:10.1002/ange.201507978 · Cited by 40
Targeted covalent inhibitors of MDM2 using electrophile-bearing stapled peptides
Charoenpattarapreeda, J., Tan, Y. S., Iegre, J., Walsh, S. J., Fowler, E., Eapen, R. S., Wu, Y., Sore, H. F., Verma, C. S., Itzhaki, L., et al. (2019) · Chemical Communications · doi:10.1039/c9cc04022f · Cited by 35
Wu, X., Wang, L., Han, Y., Regan, N., Li, P.-K., Villalona, M. A., Hu, X., Briesewitz, R., & Pei, D. (2011) · ACS Combinatorial Science · doi:10.1021/co200057n · Cited by 36
Protein Hot Spots: The Islands of Stability
Kuttner, Y. Y., & Engel, S. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.11.009 · Cited by 32
Computed cancer interactome explains the effects of somatic mutations in cancers
Zhang, J., Pei, J., Durham, J., Bos, T., & Cong, Q. (2022) · Protein Science · doi:10.1002/pro.4479 · Cited by 31
Screening-based approaches to identify small molecules that inhibit protein–protein interactions
Choi, S., & Choi, K.-Y. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1280456 · Cited by 29
Bohnuud, T., Kozakov, D., & Vajda, S. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003872 · Cited by 27
Miglianico, M., Nicolaes, G. A. F., & Neumann, D. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01201 · Cited by 24
Reliable prediction of protein–protein binding affinity changes upon mutations with Pythia-PPI
Tao, F., Sun, J., Gao, P., Gao, G. F., & Wu, B. (2025) · National Science Review · doi:10.1093/nsr/nwaf231 · Cited by 10
Protein-Protein Interactions as Drug Targets
Wendt, M. D. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_1 · Cited by 9
Mapping functional regions of essential bacterial proteins with dominant-negative protein fragments
Savinov, A., Fernandez, A., & Fields, S. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200124119 · Cited by 8
Rewiring protein binding specificity in paralogous DRG/DFRP complexes
(2024) · doi:10.1016/j.str.2024.08.012 · Cited by 2
Genome-scale annotation of protein binding sites via language model and geometric deep learning
(2023) · doi:10.1101/2023.11.02.565344 · Cited by 2
Genome-scale annotation of protein binding sites via language model and geometric deep learning
Yuan, Q., Tian, C., & Yang, Y. (2024) · doi:10.7554/elife.93695.2
Metadata
- Authors
- Wells, J. A., & McClendon, C. L.
- Venue
- Nature
- Published
- 2007-12
- Volume
- 450
- Issue
- 7172
- Pages
- 1001-1009
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2056169996
- Cited by
- 1,960
- References
- 98
- FWCI
- 117.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.